These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37834994)

  • 41. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
    Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilar biological drugs in the treatment of inflammatory bowel diseases.
    Kaniewska M; Eder P; Gąsiorowska A; Gonciarz M; Kierkuś J; Małecka-Panas E; Rydzewska G
    Prz Gastroenterol; 2019; 14(4):223-227. PubMed ID: 31988667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilars in Pediatric IBD: Updated Considerations for Disease Management.
    Dipasquale V; Cucinotta U; Romano C
    Biologics; 2022; 16():57-66. PubMed ID: 35721798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases.
    Park SH; Park JC; Lukas M; Kolar M; Loftus EV
    Intest Res; 2020 Jan; 18(1):34-44. PubMed ID: 32013313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.
    Armuzzi A; Avedano L; Greveson K; Kang T
    J Crohns Colitis; 2019 Feb; 13(2):259-266. PubMed ID: 30285235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
    Barberio B; Cingolani L; Canova C; Barbieri G; Sablich R; Urbano MT; Bertani L; Costa F; Bodini G; Demarzo MG; Ferronato A; Buda A; Melatti P; Massimi D; Savarino EV; Zingone F
    Therap Adv Gastroenterol; 2021; 14():17562848211031420. PubMed ID: 34349836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence.
    Dipasquale V; Cicala G; Spina E; Romano C
    Front Pharmacol; 2022; 13():846151. PubMed ID: 35370732
    [No Abstract]   [Full Text] [Related]  

  • 52. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.
    Petric Z; Goncalves J; Paixao P
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.
    Najeeb H; Yasmin F; Surani S
    World J Clin Cases; 2022 May; 10(14):4327-4333. PubMed ID: 35663066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilars in IBD: from theory to practice.
    Danese S; Bonovas S; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council.
    Cohen AD; Vender R; Naldi L; Kalb RE; Torres T; Rajagopalan M; van der Walt J; Puig L; Young HS
    JAAD Int; 2020 Dec; 1(2):224-230. PubMed ID: 34409344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adherence patterns in naïve and prevalent use of infliximab and its biosimilar.
    Alanaeme CJ; Sarvesh S; Li CY; Bernatsky S; Curtis JR; Yun H
    BMC Rheumatol; 2022 Nov; 6(1):65. PubMed ID: 36316762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
    Sullivan E; Piercy J; Waller J; Black CM; Kachroo S
    PLoS One; 2017; 12(4):e0175826. PubMed ID: 28410403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.
    D'Amico F; Pouillon L; Argollo M; Hart A; Fiorino G; Vegni E; Radice S; Gilardi D; Fazio M; Leone S; Bonovas S; Magro F; Danese S; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Feb; 52(2):138-142. PubMed ID: 31812570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.